Crism Therapeutics (LSE:CRTX) Net Margin %: -421.21% (As of Dec. 2025)


What is Crism Therapeutics Net Margin %?

Crism Therapeutics LSE:CRTX -2.56% Net Margin % is -421.21% as of Dec. 2025. The stock has 3 warning signs investors should review. Among 942 Biotechnology companies, Crism Therapeutics ranks worse than 76.65% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Crism Therapeutics's Net Income for the six months ended in Dec. 2025 was £-0.97 Mil. Crism Therapeutics's Revenue for the six months ended in Dec. 2025 was £0.23 Mil. Therefore, Crism Therapeutics's net margin for the quarter that ended in Dec. 2025 was -421.21%.

The historical rank and industry rank for Crism Therapeutics's Net Margin % or its related term are showing as below:

LSE:CRTX' s Net Margin % Range Over the Past 10 Years
Min: -2428   Med: -823.81   Max: -435.56
Current: -823.81

LSE:CRTX's Net Margin % is ranked worse than
76.65% of 942 companies
in the Biotechnology industry
Industry Median: -88.815 vs LSE:CRTX: -823.81

Crism Therapeutics  (LSE:CRTX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Crism Therapeutics Net Margin % Related Terms

Crism Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for Crism Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crism Therapeutics Net Margin % Chart

Crism Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -435.56 -2,428.00 -823.81

Crism Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -435.71 0.00 -2,376.00 0.00 -421.21

LSE:CRTX vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Crism Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Crism Therapeutics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Crism Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Crism Therapeutics's Net Margin % falls into.


Crism Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Crism Therapeutics's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-1.903/0.231
=-823.81 %

Crism Therapeutics's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-0.973/0.231
=-421.21 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -421.21% mean?
Crism Therapeutics (LSE:CRTX) has a Net Margin % of -421.21% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Crism Therapeutics and its competitors. According to the industry distribution chart, Crism Therapeutics ranks #722 out of 942 companies in the Biotechnology industry, placing it in the top 76.6%.
Is Crism Therapeutics' Net Margin % too high?
Crism Therapeutics' current Net Margin % is -421.21%. Based on the distribution chart, Crism Therapeutics ranks #722 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Crism Therapeutics' Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Crism Therapeutics ranks #722 out of 942 companies for Net Margin %. This places Crism Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Crism Therapeutics and its competitors. Crism Therapeutics's current Net Margin % is -421.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crism Therapeutics stock overvalued right now?
Crism Therapeutics (LSE:CRTX) has a current Net Margin % of -421.21%. The current Net Margin % is -421.21%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Crism Therapeutics (LSE:CRTX), the current Net Margin % is -421.21% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Crism Therapeutics Business Description

Address Kingston Chambers, P.O. Box 173, Tortola, Road Town, VGB
Crism Therapeutics Corp has developed a drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. Its product ChemoSeed which is in its clinical trial phase, can be implanted directly into the tumour or the resection margin following the removal of a tumour. The company also provides consultancy and formulation services to its clients assisting them with pharmaceutical formulation and development.